C4 glomerulopathy Medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

The mainstay of treatment for C4 glomerulopathy is antihypertensive and lipid-lowering drugs.

Medical Therapy

Pharmacologic medical therapies for C4 glomerulopathy include^[1]^[2]:

References

↑ Appel, Gerald B.; Cook, H. Terence; Hageman, Gregory; Jennette, J. Charles; Kashgarian, Michael; Kirschfink, Michael; Lambris, John D.; Lanning, Lynne; Lutz, Hans U.; Meri, Seppo; Rose, Noel R.; Salant, David J.; Sethi, Sanjeev; Smith, Richard J.H.; Smoyer, William; Tully, Hope F.; Tully, Sean P.; Walker, Patrick; Welsh, Michael; Würzner, Reinhard; Zipfel, Peter F. (2005). “Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update”. Journal of the American Society of Nephrology. 16 (5): 1392–1403. doi:10.1681/ASN.2005010078. ISSN 1046-6673.
↑ Ali, Arshad; Schlanger, Lynn; Nasr, Samih H.; Sethi, Sanjeev; Gorbatkin, Steven M. (2016). “Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure”. American Journal of Kidney Diseases. 67 (3): 479–482. doi:10.1053/j.ajkd.2015.10.020. ISSN 0272-6386.

Overview